Jeffrey S. Borer mainly focuses on Internal medicine, Cardiology, Heart failure, Ejection fraction and Heart rate. His Internal medicine study incorporates themes from Anesthesia, Placebo and Surgery. His Cardiology research is multidisciplinary, incorporating elements of Left ventricular hypertrophy and Blood pressure.
The various areas that he examines in his Heart failure study include Hazard ratio, Ivabradine and Intensive care medicine. His Ejection fraction research includes elements of Frame rate, Diastole, Coronary circulation and Cineangiography. His Heart rate research integrates issues from Coronary artery disease, Cardiac output and Framingham Risk Score.
Internal medicine, Cardiology, Heart failure, Ejection fraction and Regurgitation are his primary areas of study. The Internal medicine study which covers Surgery that intersects with Valve replacement. His work carried out in the field of Cardiology brings together such families of science as Asymptomatic and Heart rate.
His work in Heart failure covers topics such as Intensive care medicine which are related to areas like Clinical trial. His Ejection fraction research includes themes of Diastole and Cineangiography. His Ivabradine research is multidisciplinary, relying on both Anesthesia, Sinus rhythm, Placebo and Bradycardia.
Jeffrey S. Borer spends much of his time researching Internal medicine, Cardiology, Heart failure, Ivabradine and Heart rate. His studies deal with areas such as Placebo and Anesthesia as well as Internal medicine. His study in the field of Ejection fraction, Cardiac resynchronization therapy and QRS complex is also linked to topics like In patient.
Jeffrey S. Borer has included themes like Mitral valve, Mitral regurgitation, Myocardial infarction and Intensive care medicine in his Heart failure study. His biological study spans a wide range of topics, including Coronary artery disease, Mineralocorticoid receptor, Post-hoc analysis, Cardiovascular agent and Sinus rhythm. His research in Heart rate intersects with topics in Framingham Risk Score, Proportional hazards model and Angina.
His primary areas of investigation include Internal medicine, Cardiology, Heart failure, Ivabradine and Heart rate. His study in Internal medicine is interdisciplinary in nature, drawing from both Placebo and Anesthesia. The various areas that Jeffrey S. Borer examines in his Cardiology study include Blood pressure and Confidence interval.
His Heart failure study integrates concerns from other disciplines, such as Electrocardiography and Surgery. He interconnects Post-hoc analysis, Beta blocker, Cardiovascular agent, Myocardial infarction and Sinus rhythm in the investigation of issues within Ivabradine. Jeffrey S. Borer has researched Heart rate in several fields, including Creatinine, Cardiac output, Framingham Risk Score and Proportional hazards model.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.
Karl Swedberg;Michel Komajda;Michael Böhm;Jeffrey S Borer.
The Lancet (2010)
Targeted Anticytokine Therapy in Patients with Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)
Douglas L. Mann;John J.V. McMurray;Milton Packer;Karl Swedberg.
Resting heart rate in cardiovascular disease.
Kim Fox;Jeffrey S. Borer;A. John Camm;Nicolas Danchin.
Journal of the American College of Cardiology (2007)
Real-time radionuclide cineangiography in the noninvasive evaluation of global and regional left ventricular function at rest and during exercise in patients with coronary-artery disease.
J S Borer;S L Bacharach;M V Green;K M Kent.
The New England Journal of Medicine (1977)
Left ventricular hypertrophy in patients with hypertension: importance of blood pressure response to regularly recurring stress.
R. B. Devereux;T. G. Pickering;Gregory A Harshfield;H. D. Kleinert.
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
Michael Böhm;Karl Swedberg;Michel Komajda;Jeffrey S Borer.
The Lancet (2010)
Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex
Frank Ruschitzka;William T. Abraham;Jagmeet P. Singh;Jeroen J. Bax.
The New England Journal of Medicine (2013)
Consensus recommendations for the management of chronic heart failure: Introduction
Milton Packer;Jay N. Cohn;William T. Abraham;Wilson S. Colucci.
American Journal of Cardiology (1999)
Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial.
Jeffrey S. Borer;Kim Fox;Patrice Jaillon;Guy Lerebours.
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis
Steven E. Nissen;Neville D. Yeomans;Daniel H. Solomon;Thomas F. Lüscher.
The New England Journal of Medicine (2016)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: